ACIU
ACIU clinical trials: AC Immune SA
Every trial on ClinicalTrials.gov where AC Immune SA is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 10
- Trials linked
- 8
- As lead sponsor
- 2
- As collaborator
- 2
- Primary completions as lead sponsor, next 90 days
ACIU on the catalyst calendar · ACIU registry changes
- Primary completion Dec 2026Sponsor estimateEarly Phase 1NCT06891703[18F]ACI-15916 PET in α-synucleinopathiesAC Immune SA · Parkinson's Disease (PD)RecruitingACIULead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 2028Sponsor estimatePhase 2NCT06015841A Study to Evaluate the Effects of ACI-7104.056 in Patients With Early Stages of Parkinson's DiseaseAC Immune SA · Parkinson DiseaseActive, not recruitingACIULead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 1NCT07463196A Study Investigating the Safety, Absorption, Elimination, and the Effect on the Immune System of ACI-19764 in Healthy Participants and...AC Immune SA · Healthy ParticipantsRecruitingACIULead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 2026Sponsor estimateEarly Phase 1NCT06891716[18F]ACI-19626 PET in TDP-43 ProteinopathiesAC Immune SA · Frontotemporal Dementia (FTD)RecruitingACIULead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 2029Sponsor estimatePhase 1/Phase 2NCT05462106A Study to Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Syndrome (ABATE Study)AC Immune SA · Amyloid PlaqueRecruitingACIULead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 5, 2023ActualPhase 1/Phase 2NCT04445831A Study to Evaluate the Safety, Tolerability and Immunogenicity of Tau Targeted Vaccines in Participants With Early Alzheimer's DiseaseAC Immune SA · Alzheimer's DiseaseCompletedACIULeadJNJCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 2024Sponsor estimatePhase 2NCT04373616A Study of ACI-24 in Adults With Down SyndromeAC Immune SA · Down SyndromeWithdrawnACIULead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 2020ActualPhase 1NCT02738450Safety, Tolerability and Immunogenicity of ACI-24 Vaccine in Adults With Down SyndromeAC Immune SA · Down SyndromeCompletedACIULead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 26, 2024ActualEarly Phase 1NCT06445465Study to Evaluate a Potential PET Radioligand for Imaging Alpha-synuclein Deposits in the BrainInvicro · Alpha-SynucleinopathyCompletedACIUCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 1, 2021ActualNo phase registeredNCT05067192Optimization of Morphomer-based Alpha-synuclein PET TracersSkane University Hospital · Parkinson DiseaseCompletedACIUCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 10 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner